...Montagnola Managerial Accounting Individual Project When making my decision to obtain my PharmD. back in high school, I knew the world of opportunity that was awaiting me along with the chances to advance. However, when I decided to obtain my MBA in Healthcare Systems Management, another world of opportunity suddenly was placed in front of me. There are unlimited placements for a pharmacist in today’s society. Now when adding a MBA degree to my medical background, the placements seem endless. Mainly, numerous jobs in pharmaceutical companies suddenly become attainable and appealing. This is where the focus of my learning and goals has taken me, to be able to become an executive or director at a large pharmaceutical company, such as Pfizer or Merck. Nevertheless, much goes into a decision like this when weighing the options of accepting a job in this setting. How do I stand financially at this moment and current income? How would I stand if I were to accept the job offer that I have been offered? Does this company offer advancement for me to attain more prestigious and higher paying jobs? Does this company have a sustainable business model that will allow me to maintain a job for the future? As you can see, all these aspects play a role and that is only the tip of the inquiry. So how does one weigh the options of accepting a job offer knowing the circumstances in which they lie? I believe this process starts with determining the budget you are on at the moment and being able...
Words: 3185 - Pages: 13
...brand loyalty patterns and medical condition. [2] Segmentation of market is one of the crucial elements of marketing strategy. Criteria depend mainly on nature of market, therefore creating a problem in deciding the actual method. Maslow hierarchy of needs also explains about satisfying the customer needs in a vertical arranged pyramid with primary psychological needs at the bottom step and with self-actualization needs at highest step with safety needs, belonging needs and esteem needs as intermediate steps in the hierarchy. For my research, I have chosen Pfizer and will explain its segmentation process using Lipitor as an example. Pfizer: Pfizer is one of the world’s largest pharmaceutical company with its portfolio including human and biologic, small molecular medicines, vaccines, nutritional and consumer products. It is located in more than 150 countries with it’s headquarter in New York. Pfizer acquired Wyeth in October ’09 for $68 billion. Its main...
Words: 1436 - Pages: 6
...Current policy and strategy of Pfizer Company The Pfizer Company planning to implement the following strategies due to its lost: Strategic priorities of the merger: Strengthens platforms for improved, consistent and stable earnings growth (1) Definitively address revenue loss from the loss of exclusivity from hypertension drug Lipitor; (2) Forms broad, diversified portfolio of growth drivers; and (3) Supports continuing progress in establishing a lower, more flexible cost base. Drives improved performance through flexible business model (1) Focused, agile business units; (2) Backed by resources, scale of global enterprise; and (3) Significant financial resources available for investment. Extends global health care leadership (1) Human, animal, consumer health; nutritionals; (2) Primary and specialty care; (3) Vaccines, biologics and small molecules; and (4) Developed and emerging markets. Enhances ability to meet unmet needs of patients, physicians and other customers (1) Pipeline portfolio in “invest to win” disease areas; (2) Enhances scientific, manufacturing and pharmaceutical science capabilities; and (3) Provides the best opportunities for world class, high performing talent. In addition, the following strategic points will be followed: (1) Become a leader in biologics; (2) Enter the vaccines market; (3) Expand and invest to win areas; (4) Strengthen leadership in emerging markets; ...
Words: 333 - Pages: 2
...| Pfizer Stock Report | | Fall 2013 Research Project | | Pfizer Stock Report | | Fall 2013 Research Project | Saint Joseph’s University Contents II. Introduction 2 III. Macroeconomic Review 3 IV. Stock Market Analysis 6 V. Industry Analysis 8 VI. Company Strategic Analysis 10 VII. Company Financial Analysis 12 VIII. Application of Valuation Methodologies 13 IX. Conclusion and Recommendations 15 X. Exhibits 16 A. Exhibit A 17 B. Exhibit A 17 XI. References 18 Introduction Pfizer, headquartered in New York, NY, is committed to applying science and global resources to improve the health and well-being of individuals of all stages of life. Ian Read, CEO, leads the company through innovation and solid long term performances on the NYSE. Pfizer is also on the London, Euronext and Swiss exchanges. They make every effort to provide everybody with access to affordable, top of the line, safe remedies and health related services to those in need. Some of Pfizer’s most famous products include, Lipitor, Lyrica, Diflucan, Zithromax, Viagra, and Celebrex. Pfizer is committed to providing sustainable solutions to the biggest health issues in the world by continuously reviewing and updating their products and services to reduce their environmental footprints. The company maintains the highest ethical standards in all that they do such as sales and marketing to research and development. Pfizer, along with all industry...
Words: 4411 - Pages: 18
...Pfizer: Ethics and Leadership The selection process used by Pfizer to find a successor to CEO William Steere, who had lead the company to the top of the pharmaceutical industry, lacked a system of checks and balances resulting in a power struggle that ultimately led to distrust and the unraveling of Pfizer’s top brass by an outsider . The power struggle that erupted within Pfizer demonstrates how ethical breaches occur under specific conditions and the resulting damage. It is fascinating to observe how the unethical actions of a few individuals can spiral through an entire organization negatively affecting both the companies and their stakeholders. An economic analysis of Pfizer highlights the mismanagement of resources and the ensuing social and financial costs. Pfizer was founded in 1849 by Charles Pfizer and Charles Erhart as a fine chemicals business in Brooklyn New York. In the 1950’s the company changed its focus from fine chemicals into a research based pharmaceutical company. Pfizer’s growth exploded in the 1980’s and 1990’s with the success of drugs like Lipitor and Viagra. Led by William Steere and fueled by profits from Lipitor, Pfizer was entering its glory years. Under Steere Pfizer stock rose to a record high of $49 a share. When Steere took control in 1991 his emphasis for Pfizer was research and development of pharmaceuticals. Pfizer became a benchmark in the pharmaceutical industry and “was ranked among America’s best managed and most admired companies...
Words: 2173 - Pages: 9
...Pfizer – Wyeth Acquisition Abstract The board of Pfizer, the world’s largest drug maker, has agreed to acquire a long-time rival, Wyeth, for $68 billion. The Pfizer-Wyeth merger will create a prescription pharmaceutical company of extraordinary scale. Despite long-term patent and marketing challenges, most industry observers believe Pfizer has little choice but to engage in some type of major acquisition, especially given the recent loss of income on Lipitor. Pfizer needs to reassure its investors that it can get back on track. With having to freeze its dividends, hundreds of layoffs, and stock prices falling, it is imperative to convince the stakeholders that Pfizer will come out of this economic dilemma on top. The acquisition with Wyeth will reduce Pfizer’s negative sales outlook; however, there is only one route to delivering profit growth to investors, and that is by buying growth and cutting costs. Pfizer has announced that it expects to create savings of $4 billion by the third year after closing the acquisition. This is in part due to the 15% reduction in Pfizer-Wyeth’s combined workforce. After the merger, Pfizer will operate through a patient-centric business units in two major areas, biopharmaceuticals and diversified businesses. Its biopharmaceutical business units are emerging markets Where as Pfizer currently has one of the largest sales forces in the industry, Wyeth’s antibiotics and specialty drugs will not require a lot of marketing to consumers...
Words: 604 - Pages: 3
...An innovative culture can boost a companies brand value, because consumers associate the company with the latest products. Besides the brand boost, new products can help a company stay competitive in a tough market. If a company has the best product in a segment, they are likely to gain market share in that segment. * Other points to consider: * Lipitor is the first choice of drug for treatment of high cholesterol. * Lipid regulator market will continue to generate high revenues. * Pfizer, leading pharmaceutical company, most profitable * Pfizer has well respected name all over the world and has some of the top research, advertising, financial and marketing talent * Lipitor recommended by American hearth association. * High Cholesterol, which is a common problem across the globe is only likely to increase with rapidly aging population specially in the US and rise in obesity levels. Weaknesses * Co-marketing agreement for pfizer: * Co-marketing agreements can...
Words: 833 - Pages: 4
...spending years of effort to integrate Warner Lambert and Pharmacia into Pfizer, should its management have avoided another huge acquisition like Wyeth? Should Pfizer have gone after smaller bio tech firms in a series of small acquisitions in 2008 and 2009? A number of these bio tech firms could have been acquired for the $68 billion price of the huge Wyeth acquisition. Present arguments for and against buying several small firms versus one large firm. In my opinion, when it comes to the option of bigger or smaller firm acquisition, Pfizer should have invested in a large acquisition like wryeth. This is because Pfizer’s focus is not really on how many firms it can acquire but proceeds and profit margins these acquisitions can bring in. Basing on the case, its previous large acquisitions such as Warner Lambert and Pharmacia. In 2000 and 2003 where quiet good investments bringing in large profit margin of up to 90% from the Warner. A large problem of staffing is also worsened by over acquisition. According to the case overtime acquired firms have brought in excess staff for Pfizer and this has become a problem as managers for each line have increased and thus larger costs in terms of salaries as well. Larger firm acquisitions have also evidently brought stronger products than Pfizer itself can produce. Drugs such as Lipitor from an acquired firm brought in sales of about 12 billion annually while Pfizer produced drugs have failed i.e. T-pill Furthermore larger acquisitions...
Words: 1587 - Pages: 7
...| Pfizer | Memo To: Professor Fear From: Alexander Ouji Date: [ 1/30/2012 ] Re: Pfizer Overview Pfizer is the largest pharmaceutical company in the world. Upon reviewing annual reviews and financial reports from the past 5 years, Pfizer, although dealing with many issues both inherent and external, is keeping a stable financial condition as well as keeping its strategic operations aligned with its goals and objectives. The following is an overview which will further explain the company’s management and financial climate. Strategy Pfizer’s broad goal is to apply science and global resources to improve health and well-being at every stage of life.[1] Their strategy has been to essentially “beat their competitors to the punch” by being the first to develop and market pharmaceutical drugs. They do this by investing heavily in research and development. In the past six years, their average research and development expense has been 8 billion dollars, with 2010 being the highest amount at 9.4 billion.[2] They have continued to spend approximately this amount despite continued efforts to reduce costs in certain parts of their research dealing mainly with diseases including cardiovascular. With such large sums of money being invested in research and development, the huge risks involved highlights the confidence they have in their talent in terms of successfully developing new, brand pharmaceutical drugs. Pfizer is constantly looking to diversify its portfolio...
Words: 1871 - Pages: 8
...Pfizer Stock Analysis Pfizer (NYSE: PFE) is involved in the development, manufacturing and marketing of pharmaceutical products. The industry is intensely competitive and there are a few unique characteristics. Pharmaceutical products have long and expensive development periods – upwards of ten years and $100 million depending on the nature of the drug and the scope of the clinical trials process. In order to encourage companies to engage in innovation, companies are given lengthy patent protection for their drugs upon receiving regulatory approval. This allows them to control rates so that they may recover the development cost. A product brought to market is often highly lucrative, so success in the industry depends largely on the firm’s ability to bring product to market and capitalize on the monopoly rates. Pfizer is the world’s largest pharmaceutical firm, with annual sales near $50 billion. After the sale of its consumer health-care division to J&J, prescription drugs now account for more than 90% of sales. Top sellers include cholesterol-lowering Lipitor, Celebrex for arthritis, Viagra for impotence, and Lyrica for epilepsy and some types of neuropathic pain. Recently approved drugs with blockbuster potential include oncology drug Sutent and Chantix for smoking cessation. As most pharmaceutical companies’ in the market, in this type of business it is not simple since there is a lot of research and the development of new drugs in regular basis. Most stocks...
Words: 1245 - Pages: 5
...Corporate News: Pfizer Wins Prevnar 13 Approval, In Quick Boost From Wyeth Deal Rockoff, Jonathan D. Wall Street Journal, Eastern edition [New York, N.Y] 25 Feb 2010: B.4. Turn on hit highlighting for speaking browsers by selecting the Enter button Hide highlighting Abstract (summary) Translate AbstractTranslate Press the Escape key to closeTranslate [[missing key: loadingAnimation]] The Food and Drug Administration approved Prevnar 13 for prevention of "pneumococcal" illnesses, such as ear infections, sepsis and meningitis, in infants and young children. Full Text Translate Full textTranslate Press the Escape key to closeTranslate [[missing key: loadingAnimation]] Turn on search term navigationTurn on search term navigation A new version of the Prevnar childhood vaccine won regulators' approval Wednesday, giving maker Pfizer Inc. a quick and important lift from its takeover of rival Wyeth last year. The Food and Drug Administration approved Prevnar 13 for prevention of "pneumococcal" illnesses, such as ear infections, sepsis and meningitis, in infants and young children. An advisory panel to the Centers for Disease Control and Prevention swiftly recommended the vaccine's routine use. Pfizer has been counting on the new vaccine, and the approval marks an important early success for the Wyeth deal. After struggling to find new blockbusters, Pfizer bought Wyeth for $68 billion to help offset sales it will lose when cholesterol drug Lipitor loses patent protection late...
Words: 749 - Pages: 3
...Business Investigation of Pfizer Inc. World’s most profitable and privately sponsored research based biomedical organization is Pfizer Inc. Pfizer became the biggest pharmaceutical company after merging with Warner Lambert in the month of July, 2000. Huge global sales with a large number of popular products, a valuable and ingenious R&D division, all these have taken the firm to the peak of the industry. There lie some secrets behind the success of Pfizer that it follows while operating the business. They are: * Maximizing short and longstanding sales revenue. * Establishing a more flexible but lower cost base some places in Asia. * Creating smaller, more customer focused and responsible operating areas. * Engaging more customers, patients, tolerant, medical doctors and other collaborators. * Making Pfizer a place where everyone enjoys their job. Pfizer has altered the business method along with the change of the global business environment by the end of year 2007. This company currently operates in places where there are fewer constraints, less officialdom and minimum operating costs. Pfizer has reorganized their cost base to run with flexibility. Conversely, this company is now making things easier for the R&D division to create cooperation in all the research teams who are expert in different sides to increase efficiency by using all the research team in functioning together in any particular work base. The upward growth trend of pharmaceutical...
Words: 320 - Pages: 2
...Pfizer Executive Summary Company Overview World’s largest global research-based biomedical and pharmaceutical company that discovers, develops, manufactures and markets safe and effective medicines. Mission To be the world’s most valued company to patients, customers, colleagues, investors, business partners and the communities where we work and live. Pharmaceutical Products Aricept Genotropin Spiriva Aromasin Geodon/Zeldox Sutent Caduet Lipitor Vfend Camptosar Lyrica Viagra Celebrex Norvasc Xalatan/Xalacom Chantix Rebif Zmax Detrol/Detrol LA Relpax Zoloft Eraxis Revatio Zyvox Animal Health Products BoviShield Draxxin RespiSure/Stellamune Cerenia Excede Revolution/Stronghold Clavamox/Synulox Improvac Rimadyl Convenia Lutalyse Silentrol Dectomax Naxcel/Excenel Financials Stock Symbol: PFE Price Range: $11-$18 Sales (2008): $48,296,000,000 Net Income: $8,104,000,000 Net Assets: $109,892,000,000 Key Executives CEO: Jeff Kindler CFO: Frank D'Amelio CMO (Chief Medical Officer): Freda C. Lewis-Hall Key Competitors GlaxoSmithKline Johnson & Johnson Novartis AG Roche Holding-AG Sanofi-Aventis Mergers and Acquisitions (2008-2009) Wyeth: announcement of merger 1/26/09, biopharmaceutical Auxilium Pharmaceuticals: 12/08, develops Xiaflex-first in class biologic for treatment of Dupuytren’s contracture and Peyronie’s Disease Schering-Plough...
Words: 7035 - Pages: 29
...Elwood Leftridge Professor Joanne Land Kazlauskas GPS-4278W 05-01-2013 Putting It All Together a Look at Pfizer Pharmaceutical Company Pfizer Pharmaceutical Company is not only the world’s largest research pharmaceutical company in the world, but also the leader of technological advances. This organization has been in operation for over 160 successful years, and has over 117,000 diverse workers employed worldwide from all facets of life. It is important to employ a solid employee workforce within an organization, this can either make or break an organization. “In 2012 Pfizer was ranked #40 among Fortune 500 with 2011 revenue totaling almost 68 million dollars, and a profit margin of over 10 million dollars”(CNN Money, 2013). The purpose of this paper is to break apart Pfizer into four different organizational perspectives, analyze them, and then put them back together again. Or as with the title of the textbook (Reframing Organizations: Artistry, Choice, and Leadership. Vol. 4) suggests to reframe organizations to a particular frame or frames. The frames that I will be using to analyze Pfizer Pharmaceuticals will be the Structural Frame, the Symbolic Frame, the Human Resources Frame, as well the Political Frame. To begin, I will describe the Pfizer organization using Bolman & Deal’s Structural Frame perspective. The structural components that I will discuss will be the Division of Labor, the Leadership Structure, and Roles and Responsibilities of the organization...
Words: 5349 - Pages: 22
...order winners of the operational strategy of Pfizer Inc. Worlds’ leading pharmaceutical manufacturer A report prepared by Dr Amit Roy Contents 1.0 Executive Summary 4 2.0 Background 5 3.0 Key Financial information 5 4.0 Order Qualifiers and Order Winners 6 4.0.1 Safe clinical trials and drug delivery methods to objects 6 4.0.2 Health and safety standards 7 4.0.3 License to manufacture 7 4.0.4 Off license manufacturing 7 4.0.5 License to distribute the products in a specific regions 7 4.0.6 Quality of products 7 4.0.7 Cost 8 4.0.8 Supply chain 8 4.0.9 Capacity 8 4.0.10 Innovation 8 4.0.11 Market offering 9 4.0.12 Human resources 9 4.0 Pfizer’s broad order winners and operational strategy 9 4.1.13 Improving the Performance of the Innovative Core 9 4.1.14 Engine for Sustainable Innovation 10 4.1.15 Making the Right Capital Allocation Decisions 14 4.1.16 Earning Respect from Society 15 4.1.17 Creating an Ownership Culture 16 4.1.18 Corporate Governance 17 5.0 Conclusion 17 6.0 References 18 1.0 Executive Summary This report investigates the operational strategy of Pfizer, world’s leading pharmaceutical company in terms...
Words: 3580 - Pages: 15
